BiotechTube
ReproNovo

ReproNovo

Basel, Switzerland· Est.
repronovo.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $65M

Overview

ReproNovo is a private, clinical-stage biotech company targeting significant unmet needs in reproductive health, including male infertility and adenomyosis. The company's most advanced program, RPN-001 (leflutrozole), is in Phase 2 clinical trials in the U.S. and has received clinical trial approval in China. Backed by a seasoned leadership team and specialized international investors, ReproNovo is positioned to advance novel therapies in a large and growing global market.

Reproductive MedicineWomen's Health

Technology Platform

Small molecule therapeutics focused on modulating hormonal pathways (e.g., aromatase inhibition) for reproductive health indications.

Funding History

1
Total raised:$65M
Venture$65M

Opportunities

The significant unmet medical need in male infertility, with few drug treatments available, presents a major commercial opportunity.
Additionally, expanding the application of its lead candidate into women's health conditions like adenomyosis could open a large, underserved market and create a diversified pipeline.

Risk Factors

Key risks include clinical trial failure of its lead candidate RPN-001, regulatory hurdles in multiple geographies (U.S.
and China), and potential challenges in market adoption and reimbursement for a novel pharmaceutical in the fertility space.

Competitive Landscape

The pharmaceutical landscape for male infertility is relatively sparse, with limited direct competition, though ReproNovo may compete with off-label therapies and other biotechs exploring hormonal treatments. In women's health and ART adjuvants, competition is more active from both specialty pharma and larger medtech companies focused on fertility.

More companies in Small Molecule Drugs →More companies in Switzerland →